FDA
-
-
-
-
-
-
-
Akorn Provides Fourth Quarter and Full Year 2019 Results
-
-
-
-
-
-
-
Akorn (AKRX) Tops Q3 EPS by 6c
-
-
-
-
-
-
-
Akorn (AKRX) Announces FDA Approves Azelastine Hydrochloride Nasal Spray, 0.15%
-
-
-
-
-
-
-
Pre-Open Movers 06/25: (AGN) (PHUN) (PYX) (GRUB) (ALDX) (ABBV) (BHF) (AKRX) (more)
-
-
-
-
-
-
-
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%
-
-
-
-
-
-
-
Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
-
-
-
-
-
-
-
Akorn (AKRX) Believes Fresenius’ Amended Claims are Meritless
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

